

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangxi Institute of Biological Products Inc.

江西生物製品研究所股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6915)

**VOLUNTARY ANNOUNCEMENT
VETERINARY TETANUS ANTITOXIN PRODUCTION LINE
OFFICIALLY COMMENCED PRODUCTION**

This announcement is made by Jiangxi Institute of Biological Products Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) is pleased to announce that the veterinary tetanus antitoxin (“**Veterinary TAT**”) production line of Chifeng Bo-en Pharmaceutical Co., Ltd. (“**Chifeng Bo-en**”), a wholly-owned subsidiary of the Company, officially commenced production on July 20, 2026 in Chifeng City, Inner Mongolia Autonomous Region.

Veterinary TAT is primarily used for the prevention and treatment of tetanus in animals caused by trauma or surgery. Tetanus is a fatal infectious disease caused by the toxin produced by *Clostridium tetani* acting on the nervous system of animals. Veterinary TAT provides passive immune protection for animals by neutralizing tetanus toxin.

The Board considers that this commencement of production marks key advancement in the Group’s “human pharmaceuticals + veterinary pharmaceuticals” dual-wheel-driven strategy, expands the Group’s antiserum product portfolio from the human use field to the animal health field, provides production capacity assurance for the large-scale production and commercial promotion of veterinary antiserum products, effectively enriches the Group’s multi-category antiserum portfolio, and strengthens business growth momentum.

ABOUT CHIFENG BO-EN

Chifeng Bo-en is a veterinary pharmaceutical platform under the Group, focusing on animal health field. It serves as a key pillar of the Group's "human pharmaceuticals + veterinary pharmaceuticals" dual-wheel strategy. Chifeng Bo-en focuses on veterinary anti-infectives, immunomodulation, and reproductive management. Leveraging the Group's full-industry-chain antiserum integration platform, the Company has established a modern veterinary pharmaceutical production system that complies with China's new Veterinary GMP standards, EU GMP, and US FDA quality system requirements. Chifeng Bo-en operates three production zones and eight modern production lines, forming diversified production capabilities covering antisera, cell fermentation, biological extraction, and chemical preparations. Its product portfolio includes veterinary tetanus antitoxin, recombinant interferon- α , pig spleen transfer factor, bursal peptide, and reproductive hormones, among other series, while continuing to advance the R&D and industrialization of veterinary antisera and innovative products.

By order of the Board
Jiangxi Institute of Biological Products Inc.
江西生物製品研究所股份有限公司
Ms. Jing Yue
Chairperson and Executive Director

Hong Kong, July 27, 2026

As of the date of this announcement, the Board comprises: (i) Ms. JING Yue, Mr. YAO Xiaodong, Mr. LI Changqing and Ms. JING Ruihua as executive Directors; (ii) Ms. YU Ailian and Mr. XIAO Changqing as non-executive Directors; and (iii) Dr. ZOU Pingxue, Dr. TSANG Hiu Leong and Mr. WU Di as independent non-executive Directors.